Patient Reported Outcomes Following Percutaneous Lung Ablation

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07720102

Enrollment

Registered

2026-07-22

Start date

2026-09-01

Completion date

2028-12-31

Last updated

2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasm

Brief summary

This study evaluates satisfaction with percutaneous ablation and any symptoms experienced before and after the procedure in patients with lung tumors.

Interventions

OTHERNon-Interventional Study

Non-interventional study

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Undergoing percutaneous lung ablation

Exclusion criteria

* Decline to participate in research

Design outcomes

Primary

Measure	Time frame	Description
Symptom severity following percutaneous lung ablation	Baseline (prior to ablation), 1 day, 3 days, 7 days, 1 month, 3 months	Assessed using a study-specific survey. Participants evaluate 5 symptoms (pain, fatigue, drowsiness, shortness of breath, and disturbed sleep), each on an 11-point Likert scale of 0-10 where 0=absence of symptoms and 10=as bas as you can imagine. Higher scores indicate greater severity of symptoms.

Countries

United States

Contacts

CONTACTClinical Trials Referral Office

mayocliniccancerstudies@mayo.edu855-776-0015

PRINCIPAL_INVESTIGATORAhmad Parvinian, MD

Mayo Clinic in Rochester

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 23, 2026